|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size 8/03/17 PDL Biopharma, Inc. 8-K:2,7,9 8/03/17 4:2.9M |
Document/Exhibit Description Pages Size 1: 8-K Current Report HTML 21K 2: EX-99.1 Press Release HTML 99K 3: EX-99.2 Presentation HTML 8K 4: EX-99.3 Information Sheet HTML 89K
| Exhibit |
• | Total
revenues of $143.8 million and $189.3 million for the three and six months ended June 30, 2017, respectively. |
• | GAAP diluted EPS of $0.39 and $0.42 for the three and six months ended June 30, 2017, respectively. |
• | GAAP net income attributable to PDL’s shareholders of $60.4 million and $67.7 million for the three and six months ended June 30, 2017, respectively. |
• | Non-GAAP
net income attributable to PDL’s shareholders of $40.2 million and $53.5 million for the three and six months ended June 30, 2017. |
• | PDL completed its $30 million share repurchase program, purchasing 13.3 million shares during the four-month period from the initial announcement in March 2017 through completion in June 2017. |
• | Continue to receive royalties on Tysabri from Biogen with respect to sales of the licensed product manufactured prior to patent expiry in jurisdictions providing patent protection licenses. |
• | PDL received a royalty payment for the second quarter of 2017 in the amount of $16.3 million for royalties earned on sales of Tysabri. The duration of this royalty payment is based on the sales of product manufactured prior to patent expiry, the amount of which is uncertain. |
• | Noden US is commercializing Tekturna® and Tekturna HCT® in the United States and Noden Pharma DAC, an Irish based company, assumed commercialization responsibilities for Rasilez® and Rasilez HCT® in the rest of the world in the second half of 2017. The products are indicated for the treatment of hypertension. |
• | PDL
repurchased it’s non-controlling interest in Noden and now owns 100% of Noden and continues to hold three of five board seats. |
• | Noden and PDL are evaluating additional specialty pharma products in the form of optimized, established medicines, to acquire for Noden. |
• | Noden net revenue for the quarter ended June 30, 2017 was $16.2 million, with $12.9 million in US revenue and $3.3 million in the rest of world. |
◦ | Gross
margins on the US revenue in the second quarter were approximately 81.0 percent. |
◦ | The $3.3 million of revenue for the ex-U.S. is net of cost of goods and a fee to Novartis through its transition services agreement and will continue until marketing authorizations have been transferred. |
• | Novartis and Noden Pharma DAC are working to transfer the marketing authorizations from Novartis companies to Noden Pharma DAC or to deregister the products. |
◦ | These
transfers (specifically EU, Switzerland, Canada and Japan) have been delayed per our original plan and are now expected to take place in the fourth quarter of this year. |
◦ | Novartis has begun deregistering the product in countries in which the products have limited sales volumes and low operating margins. |
• | Noden filed its NDA for the pediatric indication and formulation of Tekturna. Approval is estimated to be sometime in the first quarter of 2018 and if approved, would grant
Tekturna and Tekturna HCT an additional six months of marketing exclusivity in the US. |
• | Noden received a paragraph IV notice letter from Anchen Pharnaceuticals advising that Anchen had submitted an ANDA referencing Tekturna 150mg an 300mg tablets and containing certifications against U.S. Patent No. 8,617,595, which is listed in the Orange Book
for Tekturna and expires on February 26, 2026. Noden filed a complaint for patent infringement in the US District Court of New Jersey against Anchen and Par Pharmaceuticals within 45 days from receipt of the paragraph IV notice letter. As a result, Anchen’s ANDA is subject to a stay of approval for up to 30 months. The proceeding is currently in the pre-trial phase. |
Fair Value as of | Change
of | Royalty Rights - | Fair Value as of | ||||||||||||||||||
(in thousands) | Ownership | Change
in Fair Value | |||||||||||||||||||
Depomed | $ | 164,070 | $ | — | $ | 51,697 | $ | 215,767 | |||||||||||||
VB | 14,997 | — | 299 | 15,296 | |||||||||||||||||
U-M | 35,386 | — | 199 | 35,585 | |||||||||||||||||
ARIAD | 108,631 | (108,169 | ) | (462 | ) | — | |||||||||||||||
AcelRx | 67,483 | — | 4,304 | 71,787 | |||||||||||||||||
Avinger | 1,638 | — | (503 | ) | 1,135 | ||||||||||||||||
KYBELLA | 10,113 | — | (6,725 | ) | 3,388 | ||||||||||||||||
$ | 402,318 | $ | (108,169 | ) | $ | 48,809 | $ | 342,958 | |||||||||||||
Change
in | Royalty Rights - | |||||||||||||||||
Cash Royalties | Fair Value | Change in Fair Value | ||||||||||||||||
Depomed | $ | 41,767 | $ | 51,697 | $ | 93,464 | ||||||||||||
VB | 701 | 299 | 1,000 | |||||||||||||||
U-M | 1,828 | 199 | 2,027 | |||||||||||||||
ARIAD | 3,081 | (462 | ) | 2,619 | ||||||||||||||
AcelRx | 46 | 4,304 | 4,350 | |||||||||||||||
Avinger | 610 | (503 | ) | 107 | ||||||||||||||
KYBELLA | 29 | (6,725 | ) | (6,696 | ) | |||||||||||||
$ | 48,062 | $ | 48,809 | $ | 96,871 | |||||||||||||
• | To date (through June 30, 2017), we have received cash royalty payments of $253.1 million of the $240.5 million investment. |
• | Glumetza (and authorized generic version) royalty: 50% of net sales less COGS continues so long as the products are being commercialized. PDL is auditing Valeant. |
• | In
July 2017, PDL received a royalty payment from Valeant in the amount of $6.6 million for royalties earned on sales of Glumetza for the month of June. The royalty payment included royalties related to the authorized generic version of Glumetza. This payment will be recorded as part of PDL’s third quarter of 2017 revenue. |
• | Recent product approvals, Jentadueto XR, Invokamet XR and Synjardy XR have yielded $17 million in milestones in 2016 and started generating royalties to PDL. |
• | Low to mid-single digit royalties to PDL on new product approvals expected to continue to 2023 for Invokamet XR and 2026 for Jentadueto XR and Synjardy XR. |
Carrying Value | Fair Value Level 2 | Fair Value Level 3 | Carrying
Value | Fair Value Level 2 | Fair Value Level 3 | |||||||||||||||||||||||||
(In thousands) | ||||||||||||||||||||||||||||||
Assets: | ||||||||||||||||||||||||||||||
Wellstat
Diagnostics note receivable | $ | 50,191 | $ | — | $ | 51,315 | $ | 50,191 | $ | — | $ | 52,260 | ||||||||||||||||||
Hyperion
note receivable | 1,200 | — | 1,200 | 1,200 | — | 1,200 | ||||||||||||||||||||||||
LENSAR
note receivable | — | — | — | 43,909 | — | 43,900 | ||||||||||||||||||||||||
Direct
Flow Medical note receivable | — | — | — | 10,000 | — | 10,000 | ||||||||||||||||||||||||
kaléo
note receivable | 146,654 | — | 143,591 | 146,685 | — | 142,539 | ||||||||||||||||||||||||
CareView
note receivable | 19,148 | — | 19,300 | 18,965 | — | 19,200 | ||||||||||||||||||||||||
Total | $ | 217,193 | $ | — | $ | 215,406 | $ | 270,950 | $ | — | $ | 269,099 | ||||||||||||||||||
• | In NY court action commenced by PDL to collect from related entities who are guarantors of the loan, the judge ruled in favor of PDL. On appeal, the appellate division of the NY court reversed on procedural grounds the portion of the decision granting PDL summary judgment, remanding the case to the trial division for a plenary action. The action is currently before the NY trial court and in the pre-trial phase. The parties will have the opportunity to conduct discovery and file dispositive motions prior to trial. No trial date has been set yet. |
• | PDL initiated foreclosure proceedings in January 2017 which resulted in obtaining ownership of certain of the DFM assets through a wholly-owned subsidiary, DFM, LLC. |
• | PDL wrote off $51.1 million of assets against ordinary income in Q4 2016. |
• | YTD 2017, PDL monetized $8.1 million of those assets. PDL is
in the process of monetizing the ex-China assets of DFM, LLC. The amount of which recovery, if any, is unknown at this time. |
• | As of June 30, 2017 remaining foreclosed assets are recorded as assets held for sale with a carrying value of $1.9 million. |
• | LENSAR has emerged from bankruptcy, and LENSAR and PDL completed LENSAR’s financial restructuring with a court-approved
exit plan finalized on May 11, 2017. |
• | As a result of the restructuring, PDL converted most of its debt to an equity ownership position. |
• | LENSAR is now a wholly-owned subsidiary of PDL, and PDL began consolidating LENSAR’s financial statements with PDL effective May 11, 2017. |
• | Despite
Auvi-Q being voluntarily pulled from market and Sanofi returning the product right to kaléo, kaléo has made all required interest payments in full and on time to date. |
• | Auvi-Q returned to the market in February 2017 and third party reports suggest strong sales. |
• | Evzio sales have been much stronger than projected so far. This is secondary source of repayment to PDL. |
• | In the second quarter of 2017, PDL recognized and was paid $4.7 million in interest revenue from the kaléo note. |
• | A second $20.0 million tranche was to be funded by PDL upon CareView’s attainment
of specified milestones relating to the placement of CareView Systems and financial targets and was to be accomplished no later than June 30, 2017. These milestones were not achieved, and there is no additional funding obligation due to CareView from PDL. |
• | In the second quarter of 2017, PDL recognized and was paid $0.7 million in interest revenue from the CareView note. |
Queen et al. Royalties | ||||||||||
Royalty Revenue by Product ($ in 000's) * | ||||||||||
Tysabri | Q1 | Q2 | Q3 | Q4 | Total | |||||
2017 | 14,156 | 16,284 | — | — | 30,440 | |||||
2016 | 13,970 | 14,232 | 14,958 | 15,513 | 58,673 | |||||
2015 | 14,385 | 13,614 | 13,557 | 14,031 | 55,587 | |||||
2014 | 12,857 | 13,350 | 16,048 | 15,015 | 57,270 | |||||
2013 | 12,965 | 13,616 | 11,622 | 12,100 | 50,304 | |||||
2012 | 11,233 | 12,202 | 11,749 | 12,255 | 47,439 | |||||
2011 | 9,891 | 10,796 | 11,588 | 11,450 | 43,725 | |||||
2010 | 8,791 | 8,788 | 8,735 | 9,440 | 35,754 | |||||
2009 | 6,656 | 7,050 | 7,642 | 8,564 | 29,912 | |||||
2008 | 3,883 | 5,042 | 5,949 | 6,992 | 21,866 | |||||
2007 | 839 | 1,611 | 2,084 | 2,836 | 7,370 | |||||
2006 | — | — | — | 237 | 237 | |||||
* As
reported to PDL by its licensees. Totals may not sum due to rounding. | ||||||||||
Queen
et al. Sales Revenue | ||||||||||
Reported Licensee Net Sales Revenue by Product ($ in 000's) * | ||||||||||
Tysabri | Q1 | Q2 | Q3 | Q4 | Total | |||||
2017 | 471,877 | 542,761 | — | — | 1,014,638 | |||||
2016 | 465,647 | 474,379 | 498,618 | 517,099 | 1,955,743 | |||||
2015 | 479,526 | 453,786 | 451,898 | 467,735 | 1,852,945 | |||||
2014 | 428,561 | 442,492 | 534,946 | 500,511 | 1,906,510 | |||||
2013 | 434,677 | 451,358 | 387,407 | 403,334 | 1,676,776 | |||||
2012 | 374,430 | 401,743 | 391,623 | 408,711 | 1,576,508 | |||||
2011 | 329,696 | 356,876 | 388,758 | 381,618 | 1,456,948 | |||||
2010 | 293,047 | 287,925 | 293,664 | 316,657 | 1,191,292 | |||||
2009 | 221,854 | 229,993 | 257,240 | 285,481 | 994,569 | |||||
2008 | 129,430 | 163,076 | 200,783 | 233,070 | 726,359 | |||||
2007 | 30,468 | 48,715 | 71,972 | 94,521 | 245,675 | |||||
2006 | — | — | — | 7,890 | 7,890 | |||||
* As
reported to PDL by its licensee. Dates in above charts reflect when PDL receives | ||||||||||
royalties on sales. Sales occurred in the quarter prior to the dates in the above charts. | ||||||||||
Totals may not sum due to rounding. | ||||||||||
| This ‘8-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| 2/26/26 | ||||
| Filed on / For Period End: | 8/3/17 | |||
| 6/30/17 | ||||
| 5/11/17 | 8-K | |||
| 12/31/16 | 10-K | |||
| List all Filings | ||||